{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:53:27Z","timestamp":1791179607059,"version":"4.1.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In adoptive cell therapy with tumor-infiltrating lymphocytes (TILs), TILs are isolated and expanded\n                      <jats:italic>ex vivo<\/jats:italic>\n                      from an autologous tumor lesion. TIL therapy, comprising preparative lymphodepleting chemotherapy, TIL infusion, and post-infusion supportive interleukin-2 (IL-2) administration, has demonstrated efficacy in patients with metastatic melanoma. Interest in extending TIL therapy to other solid tumors is growing, and a tumor-agnostic manufacturing platform would allow first-in-human trials to be launched rapidly in these indications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study investigated whether a manufacturing process and control strategy developed for metastatic melanoma-derived TILs could be adapted into a tumor-agnostic platform for the generation of TILs from different solid tumor types, referred to as NTU101.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The feasibility of generating TILs from endometrial carcinoma (ENDC, n=9), non-small cell lung cancer (NSCLC, n=9), and penile cancer (PENC, n=10) lesions was assessed during process development (PD) runs using predefined quality criteria. Throughout PD runs, flow cytometry was used to characterize cells. When available, autologous tumor digest was used to assess the tumor-reactive potential of TILs. Based on PD experience, adjusted quality criteria were applied to manufacture one full-scale GMP NTU101-drug product (DP) per tumor type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 89% (n=25\/28) of PD NTU101-DPs manufactured met the predefined quality criteria, containing at least 0.5\u00d710^9 and 90% viable CD45+CD3+ cells, less than 1.0% of cellular impurities (viable CD45- and CD19+ cells), and a potency of more than 1.0\u00d710^3 pg\/mL IFN-\u03b3 secretion upon CD3\/CD28-polymer stimulation. Across the tumor types, PD NTU101-DPs had comparable T-cell subset and differentiation state compositions.\n                      <jats:italic>In vitro<\/jats:italic>\n                      tumor-reactive potential was detected in 82% of tested NTU101-DPs (ENDC: 71%, n=5\/7; NSCLC: 80%, n= 4\/5; and PENC: 100%, n=5\/5), although the level of reactivity will need to be confirmed with a more in-depth assay. One GMP NTU101-DP was then manufactured from each tumor type, and all three met NTU101\u2019s quality criteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The NTU101 platform produced comparable NTU101-DPs from three solid tumor types beyond melanoma, with\n                      <jats:italic>in vitro<\/jats:italic>\n                      tumor-reactive potential for some batches. This platform can be applied in TIL therapy clinical trials to generate ENDC-, NSCLC-, and PENC-derived TILs, and possibly other solid tumor types.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1854761","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:31:35Z","timestamp":1791178295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Platform-based manufacturing of tumor-infiltrating lymphocytes derived from different solid tumor types"],"prefix":"10.3389","volume":"17","author":[{"given":"Justin","family":"Lievense","sequence":"first","affiliation":[{"name":"BioTherapeutics Unit, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselotte","family":"Tas","sequence":"additional","affiliation":[{"name":"Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"van Zon","sequence":"additional","affiliation":[{"name":"BioTherapeutics Unit, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari-Anne","family":"Legu\u00e9-van Duinen","sequence":"additional","affiliation":[{"name":"BioTherapeutics Unit, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"van Amerongen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Kouwen","sequence":"additional","affiliation":[{"name":"BioTherapeutics Unit, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"van Riessen","sequence":"additional","affiliation":[{"name":"BioTherapeutics Unit, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Sluiter","sequence":"additional","affiliation":[{"name":"BioTherapeutics Unit, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeltsje","family":"Hagg","sequence":"additional","affiliation":[{"name":"BioTherapeutics Unit, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelon","family":"Badoux","sequence":"additional","affiliation":[{"name":"BioTherapeutics Unit, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Manders","sequence":"additional","affiliation":[{"name":"Department of Research Laboratory for Cell Therapy, Sanquin Blood Supply Foundation","place":["Amsterdam, Netherlands"]},{"name":"Department of Research T-cell differentiation lab, Sanquin Blood Supply Foundation","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Vedder","sequence":"additional","affiliation":[{"name":"Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Sellink","sequence":"additional","affiliation":[{"name":"Department of Research Laboratory for Cell Therapy, Sanquin Blood Supply Foundation","place":["Amsterdam, Netherlands"]},{"name":"Department of Research T-cell differentiation lab, Sanquin Blood Supply Foundation","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Seijkens","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Hartemink","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]},{"name":"Department of Pulmonary Disease, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Rijken","sequence":"additional","affiliation":[{"name":"Department of Gynaecologic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]},{"name":"Julius Centre for Health Science and Primary Care, University Medical Center Utrecht","place":["Utrecht, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Castenmiller","sequence":"additional","affiliation":[{"name":"Department of Research Laboratory for Cell Therapy, Sanquin Blood Supply Foundation","place":["Amsterdam, Netherlands"]},{"name":"Department of Research T-cell differentiation lab, Sanquin Blood Supply Foundation","place":["Amsterdam, Netherlands"]},{"name":"Oncode Institute","place":["Utrecht, Netherlands"]},{"name":"Landsteiner Laboratory, Amsterdam Medical Center","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Research Laboratory for Cell Therapy, Sanquin Blood Supply Foundation","place":["Amsterdam, Netherlands"]},{"name":"Landsteiner Laboratory, Amsterdam Medical Center","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Wolkers","sequence":"additional","affiliation":[{"name":"Department of Research T-cell differentiation lab, Sanquin Blood Supply Foundation","place":["Amsterdam, Netherlands"]},{"name":"Oncode Institute","place":["Utrecht, Netherlands"]},{"name":"Landsteiner Laboratory, Amsterdam Medical Center","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Haanen","sequence":"additional","affiliation":[{"name":"Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]},{"name":"Division of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]},{"name":"Department of Medical Oncology, Leiden University Medical Center","place":["Leiden, Netherlands"]},{"name":"The Melanoma Clinic, Centre Hospitalier Universitaire Vaudois","place":["Lausanne, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Beijnen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]},{"name":"Department of Pharmaceutical Sciences, Utrecht University","place":["Utrecht, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Nijenhuis","sequence":"additional","affiliation":[{"name":"BioTherapeutics Unit, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Jedema","sequence":"additional","affiliation":[{"name":"Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan","family":"Nuijen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.723","article-title":"Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis","volume":"35","author":"Mart\u00edn-Lluesma","year":"2024","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.7225","article-title":"Second-line therapy for endometrial cancer: The need for better options","volume":"33","author":"Fleming","year":"2015","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability\u2013high advanced endometrial cancer: Results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100879","article-title":"Controversies in NSCLC: Which second-line strategy after chemo-immunotherapy","volume":"8","author":"Moliner","year":"2023","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.02.002","article-title":"Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer","volume":"178","author":"Auclin","year":"2023","journal-title":"Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.08.001","article-title":"Second line salvage systemic therapy for advanced penile cancer","volume":"40","author":"Chahoud","year":"2022","journal-title":"Urol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00617-x","article-title":"Immune-based therapies in penile cancer","volume":"19","author":"Joshi","year":"2022","journal-title":"Nat Rev Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.03.022","article-title":"Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer","volume":"114","author":"de Jong","year":"2009","journal-title":"Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01253","article-title":"The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma","volume":"9","author":"Ottenhof","year":"2018","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7282","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer","volume":"7","author":"Zeng","year":"2016","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.3390\/cancers16203474","article-title":"Potential therapeutic targets for the treatment of HPV-associated Malignancies","volume":"16","author":"Lu","year":"2024","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627932","article-title":"Cancer vaccines, adjuvants, and delivery systems","volume":"12","author":"Paston","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0686","article-title":"Distinct mechanisms of mismatch-repair deficiency delineate two modes of response to anti\u2013PD-1 immunotherapy in endometrial carcinoma","volume":"13","author":"Chow","year":"2023","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34982","article-title":"Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers","volume":"129","author":"Nazha","year":"2023","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.21037\/tau.2017.06.27","article-title":"Relationship between human papillomavirus and penile cancer\u2014implications for prevention and treatment","volume":"6","author":"Kidd","year":"2017","journal-title":"Transl Androl Urol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2023.07.21.544585","DOI":"10.1101\/2023.07.21.544585","article-title":"Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma","author":"Chiffelle","year":"2023","journal-title":"bioRxiv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150535","article-title":"Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma","volume":"132","author":"Kristensen","year":"2022","journal-title":"J Clin Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157151","article-title":"Feasibility of manufacturing and antitumor activity of TIL for advanced endometrial cancers","volume":"26","author":"Zhang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100090","article-title":"Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments","volume":"15","author":"Castenmiller","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.07.001","article-title":"Improving lung cancer tumor-infiltrating lymphocyte (TIL) manufacturing","volume":"27","author":"Noldner","year":"2025","journal-title":"Cytotherapy"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107481","article-title":"Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients","volume":"94","author":"Aydin","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003082","article-title":"Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes","volume":"10","author":"Shah","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31824e801f","article-title":"Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment","volume":"35","author":"Jin","year":"2012","journal-title":"J Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.02.004","article-title":"Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor","volume":"16","author":"Donia","year":"2014","journal-title":"Cytotherapy"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-69","article-title":"Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE\u00ae bioreactor","volume":"10","author":"Somerville","year":"2012","journal-title":"J Transl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1483254","article-title":"Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system","volume":"15","author":"V\u00f6lzke","year":"2024","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CJI.0b013e3181f05b91","article-title":"Tumor infiltrating lymphocyte therapy for metastatic melanoma: Analysis of tumors resected for TIL","volume":"33","author":"Goff","year":"2010","journal-title":"J Immunother"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704402","article-title":"An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma","volume":"33","author":"Powell","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"45250","DOI":"10.1038\/s41598-025-29456-7","article-title":"Latent EBV reactivation drives aberrant B-cell proliferation during ex vivo tumor-infiltrating lymphocyte expansion from EBV-negative rectal cancer tumor tissue","volume":"15","author":"Petrova","year":"2025","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg7995","article-title":"Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma","volume":"9","author":"Barras","year":"2024","journal-title":"Sci Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf090","article-title":"Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial","volume":"112","author":"Tas","year":"2025","journal-title":"Br J Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31818403d5","article-title":"Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy","volume":"31","author":"Tran","year":"2008","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4499","article-title":"Neoantigen identification and response to adoptive cell transfer in anti\u2013PD-1 na\u00efve and experienced patients with metastatic melanoma","volume":"28","author":"Levi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002703","article-title":"Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma","volume":"9","author":"Borch","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1060","article-title":"Genomic correlates of outcome in tumor-infiltrating lymphocyte therapy for metastatic melanoma","volume":"28","author":"Creasy","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B47","first-page":"2025.09.23.678066","article-title":"Longitudinal profiling of tumor-reactive T cells during TIL therapy in metastatic melanoma","volume-title":"Biorxiv","author":"Sandholzer","year":"2025"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aan4931","article-title":"IL-2R\u03b2 abundance differentially tunes IL-2 signaling dynamics in CD4+ and CD8+ T cells","volume":"10","author":"Smith","year":"2017","journal-title":"Sci Signal"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh289","article-title":"IL-2 responsiveness of CD4 and CD8 lymphocytes: further investigations with human IL-2R\u03b2 transgenic mice","volume":"17","author":"Gesbert","year":"2005","journal-title":"Int Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601453","article-title":"IL-2 modulates the TCR signaling threshold for CD8 but not CD4 T cell proliferation on a single cell level","volume":"198","author":"Au-Yeung","year":"2017","journal-title":"J Immunol Baltim Md 1950"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2002.5271","article-title":"Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus","volume":"105","author":"Valenzuela","year":"2002","journal-title":"Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23193","article-title":"Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response","volume":"59","author":"Besser","year":"2020","journal-title":"Mol Carcinog"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1171","article-title":"Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma","volume":"27","author":"Seitter","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3649","article-title":"Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: Response, impact of anti-CTLA4, and biomarkers to predict clinical outcome","volume":"24","author":"Forget","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007288","article-title":"Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients","volume":"11","author":"Hall","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31825898c5","article-title":"Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes","volume":"35","author":"Friedman","year":"2012","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"B58","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12967-024-05179-7","article-title":"Mechanism of action, potency and efficacy: Considerations for cell therapies","volume":"22","author":"Simon","year":"2024","journal-title":"J Transl Med"},{"key":"B59","article-title":"Guideline on potency testing of cell based immunotherapy medicinal products for treatment of cancer - Revision 1","volume-title":"Report EMA\/CHMP\/BWP\/271475\/2006 Rev.1","year":"2016"},{"key":"B60","first-page":"P194","article-title":"Studies of key quality attributes for TIL product, LN-144","volume":"5","author":"Ritthipichai","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1190016","article-title":"Potency testing of cell and gene therapy products","volume":"10","author":"Salmikangas","year":"2023","journal-title":"Front Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26147024","article-title":"IFN\u03b3 expression correlates with enhanced cytotoxicity in CD8+ T cells","volume":"26","author":"Pattu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.04.015","article-title":"Defining the quality attributes for tumor-infiltrating lymphocyte medicinal products","volume":"31","author":"Lievense","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.11.004","article-title":"Tumor infiltrating lymphocytes streamlining a complex manufacturing process","volume":"21","author":"Hopewell","year":"2019","journal-title":"Cytotherapy"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02307-x","article-title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","volume":"68","author":"Nguyen","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B66","doi-asserted-by":"publisher","first-page":"83ra41","DOI":"10.1126\/scitranslmed.3001809","article-title":"Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity","volume":"3","author":"Hippen","year":"2011","journal-title":"Sci Transl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838904","article-title":"Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation","volume":"39","author":"Hoffmann","year":"2009","journal-title":"Eur J Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89278","article-title":"Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells","volume":"1","author":"Hirakawa","year":"2016","journal-title":"JCI Insight"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01782","article-title":"Partial CD25 antagonism enables dominance of antigen-inducible CD25high FOXP3+ regulatory T cells as a basis for a regulatory T cell-based adoptive immunotherapy","volume":"8","author":"Wilkinson","year":"2017","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally-occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1003626","article-title":"Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy","volume":"13","author":"Ge","year":"2022","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nbt.3525","article-title":"Quality cell therapy manufacturing by design","volume":"34","author":"Lipsitz","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B74","article-title":"ICH guideline Q8 (R2) on pharmaceutical development","volume-title":"Report EMA\/CHMP\/ICH\/167068\/2004","year":"2017"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1854761\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:31:38Z","timestamp":1791178298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1854761\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2026.1854761"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1854761","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1854761"}}